Immune Support Peptides: Thymosin & Immune Modulation Research
Immune-modulating peptides include Thymosin Alpha-1, which has regulatory approval in several countries outside the US for hepatitis B and C and as an immune adjuvant. This category encompasses peptides studied for their potential to modulate immune system function.
Thymosin Alpha-1 stands out as the most evidence-backed compound in this category, with approval in over 30 countries (not including the US) for viral infections, immunosuppression, and as an adjuvant therapy. Clinical trial data exists for HIV, hepatitis, sepsis, and cancer-adjunctive use. In the US, Thymosin Alpha-1 was placed on the FDA 503A Do Not Compound list in 2023, making legal access difficult. Other peptides in this category (Thymosin Beta-4, various immune modulators) have much thinner evidence profiles. Immune-focused peptide use should be approached carefully — immune "boosting" is rarely what patients actually need, and true immunomodulation carries real risks of either over-activation (autoimmune flares) or over-suppression (infection risk).
3 compounds in this category
Key Takeaways
- Thymosin Alpha-1 is approved in 30+ countries but not the US
- FDA placed Thymosin Alpha-1 on the 503A Do Not Compound list in 2023
- Evidence exists for viral infections, sepsis, and cancer adjuvant use
- Most "immune booster" peptide marketing overstates general benefit
- Immunomodulation carries real autoimmune and infection-risk tradeoffs
Compounds in This Category
TB-500Thymosin Beta-4, TB4
A naturally occurring peptide central to cell migration and tissue repair. Phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair.
SelankTP-7
A synthetic peptide analog of tuftsin, approved in Russia for anxiety and studied for nootropic and immunomodulatory properties.
Thymosin Alpha-1Tα1, Thymalfasin
A naturally occurring thymic peptide approved internationally for immune modulation, with extensive clinical data in hepatitis and cancer immunotherapy.
Frequently Asked Questions
Is Thymosin Alpha-1 legal in the US?
No. It was placed on the FDA 503A Do Not Compound list in 2023, removing the compounding pathway for legal access.
Does Thymosin Alpha-1 actually work?
Yes, for specific indications. Clinical trials support its use in chronic hepatitis, sepsis, and as a cancer treatment adjuvant. General "immune boosting" use is less well-supported.
What is the difference between Thymosin Alpha-1 and TB-500?
They are distinct peptides with different targets. Alpha-1 modulates immune function; Beta-4 (TB-500) is studied primarily for tissue repair.
Can immune peptides prevent colds or flu?
No clinical evidence supports this use. The research-supported indications are specific viral infections (hepatitis, HIV) and post-infection immune recovery.
What are the main risks?
Possible autoimmune activation, infection risk changes, and unknown long-term effects on immune homeostasis.